Max Robotics — Global Service Robot Directory + US Certification

About

Michael Goodman’s research centers on the comparative effectiveness and quality of surgical care for prostate cancer, with a particular focus on patient-reported outcomes and the real-world harms of different treatment modalities. His most cited work, “The Comparative Harms of Open and Robotic Prostatectomy in Population Based Samples” (64 citations), is a landmark population-based cohort study that critically examined whether the widespread adoption of robotic-assisted radical prostatectomy was justified by superior outcomes. By revealing conflicting evidence on disease control and functional sequelae, this study challenged assumptions and shaped ongoing debates in urologic oncology. Goodman further advanced the field by clarifying how domain scores on the EPIC-26 questionnaire translate into tangible functional outcomes, a contribution that helps patients and clinicians set realistic expectations after treatment. His work with the CEASAR study (7 citations) demonstrated that nationally endorsed quality measures for prostate cancer care are poorly linked to actual patient outcomes, highlighting critical gaps in how surgical quality is assessed. Through these contributions, Goodman has established himself as a key voice in evidence-based surgical oncology, using rigorous population-level data to inform clinical practice and health policy.